ABSTRACT
A 41-year-old female complained of impaired vision on her left eye in the past year. Her visual acuity was 20/20 on the right eye and 20/50 on the left eye. In her left eye, there was an ill-defined, irregularly pigmented, orange lesion at 7 o'clock meridian behind the iris. Standardized ultrasound A-scan and B-scan revealed a large, rounded ciliary body lesion with inner homogeneous structure, medium internal reflectivity and positive vascularity. Under the ultrasonographic diagnosis of leiomyoma, iridocyclectomy was performed. Histopathologic examination revealed ciliary body leiomyoma.
Subject(s)
Ciliary Body/diagnostic imaging , Leiomyoma/diagnostic imaging , Uveal Neoplasms/diagnostic imaging , Adult , Female , Humans , UltrasonographyABSTRACT
BACKGROUND: We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC). METHODS: Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3 and 6 months after treatment. RESULTS: All patients showed improvement in visual acuity, fluorescein angiographic leakage, and reduced or resolved neurosensory detachment following treatment. CONCLUSIONS: Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Chorioretinitis/drug therapy , Adult , Antibodies, Monoclonal, Humanized , Bevacizumab , Chorioretinitis/diagnosis , Female , Fluorescein Angiography , Humans , Injections , Male , Middle Aged , Pigment Epithelium of Eye/pathology , Pilot Projects , Serum , Tomography, Optical Coherence , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual Acuity , Vitreous BodyABSTRACT
PURPOSE: To determine short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization (CNV) in pathologic myopia. METHODS: In this prospective interventional case series, patients were treated with 2.5 mg of intravitreal bevacizumab and followed for 3 months. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and fluorescein angiography (FA) were recorded. Indications for retreatment were active leaking CNV shown by FA and presence of subretinal fluid by OCT in combination with visual disturbances. RESULTS: Fourteen patients were included, with a mean age of 53.86 +/- 16.26 years (range 29-85). Mean spherical equivalent was -13.87 +/- 3.68 diopters (-7.25 to -20.50). Minimum follow-up was 3 months. There were no adverse events. The mean initial visual acuity was 20/200 improving to 20/100 at 2 weeks, 20/80 at 4 weeks, and 20/60 at 8 and 12 weeks (P=0.007; P=0.001; P=0.005; P=0.001, respectively). Initial foveal thickness improved from 385.43 microm +/- 125.83 microm to 257.64 +/- 76.6 microm and 194.54 +/- 54.35 microm after the first and third month, respectively (P=0.001). CONCLUSIONS: Initial treatment results of patients with CNV due to pathologic myopia did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in foveal thickness and improvement in visual acuity. These favorable initial results support further larger and long-term studies.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Choroidal Neovascularization/drug therapy , Myopia, Degenerative/complications , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized , Bevacizumab , Choroidal Neovascularization/diagnosis , Choroidal Neovascularization/etiology , Female , Fluorescein Angiography , Follow-Up Studies , Fovea Centralis , Humans , Injections , Male , Middle Aged , Prospective Studies , Retina/drug effects , Retina/pathology , Tomography, Optical Coherence , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Visual Acuity/drug effects , Visual Acuity/physiology , Vitreous BodyABSTRACT
PURPOSE: To evaluate the efficacy and safety of intravitreal bevacizumab therapy for neovascular age-related macular degeneration (ARMD). METHODS: Patients with diagnosis of neovascular ARMD without any other ocular pathology were injected with 2.5 mg of intravitreal bevacizumab. A complete ophthalmic examination was undertaken in all patients, including best corrected visual acuity (BCVA), slit lamp biomicroscopy and ocular fundus examination. Ophthalmic follow-up evaluations included visual acuity measurements, optical coherence tomography (OCT) imaging, and fluorescein angiography at first, second and fourth week post injection. RESULTS: 39 eyes of 39 patients were injected. The median age was 76 years-old (range 65-90), median visual acuity was 1.18 logMAR (range 0.18-3.00) and median retinal thickness was 388 microns (range 157-1237). By the fourth week of treatment, the median visual acuity was 0.88 (range 0.18-2.78) and median retinal thickness was 247 microns (range 108-1262). Statistically significant differences were found in visual acuity and retinal thickness before and after intravitreal injection (p=0.002, p<0.001, Wilcoxon rank test). CONCLUSIONS: Our results suggest that intravitreal bevacizumab is well tolerated and is associated with improvement in BCVA and decreased mean retinal thickness by OCT. Further controlled and long term evaluation of intravitreal bevacizumab for the treatment of neovascular ARMD is warranted.
